{"id":340,"date":"2008-12-27T08:38:43","date_gmt":"2008-12-27T07:38:43","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=340"},"modified":"2013-08-23T12:45:13","modified_gmt":"2013-08-23T12:45:13","slug":"no-association-between-maternal-antiretrovirals-in-pregnancy-and-congenital-anomalies","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/340","title":{"rendered":"No association between maternal antiretrovirals in pregnancy and congenital anomalies"},"content":{"rendered":"<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>Data from the NISDI Perinatal Study conducted in Argentina and Brazil suggest no association between in utero antiretroviral (ARV) exposure and congenital anomalies (CAs).<\/strong><\/p>\n<p>The NISDI Perinatal Study is a prospective cohort study of HIV-positive women and their infants.<\/p>\n<p>In this analysis all singleton pregnancy outcomes =20 weeks gestation were included. CAs were evaluated according to the Antiretroviral Pregnancy Registry criteria. Maternal ARV regimens were categorised according to the most complex regimen received for =28 days of pregnancy.<\/p>\n<p>Of the women enrolled in this study 995\/1229 pregnancy outcomes met the inclusion criteria. The investigators reported that, of these, 60\/974 liveborn infants and 1 stillborn infant had at least one CA. They found the overall incidence of CAs in this study was 6.26 defects\/100 live births (95% CI: 4.74 -7.78).<\/p>\n<p>They reported no statistically significant differences in the proportion of pregnancy outcomes with CAs according to: whether maternal ART was initiated before conception (p=0.86); the most complex ARV regimen received during pregnancy (p=0.45) or during the 1st trimester (p=0.06).<\/p>\n<p>They wrote: &#8220;In this study population, preliminary results suggest CAs were not associated with exposure to ARVs at conception or most complex regimen received during the first trimester or during pregnancy overall.&#8221;<\/p>\n<p>Reference:<\/p>\n<p>Joao E, Calvert GA, Krauss M et al. Maternal antiretrovirals during pregnancy and infant congenital anomalies: The NISDI Perinatal Study. 48th ICAAC, 25-28 October 2008. Washington. Abstract H-457.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base Data from the NISDI Perinatal Study conducted in Argentina and Brazil suggest no association between in utero antiretroviral (ARV) exposure and congenital anomalies (CAs). The NISDI Perinatal Study is a prospective cohort study of HIV-positive women &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,35],"tags":[102],"class_list":["post-340","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pmtct-and-maternal-health","tag-icaac-48th-2008"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=340"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/340\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}